FDA · United States
carboplatin — FDA regulatory status
carboplatin (CARBOPLATIN ACCORD) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- CARBOPLATIN ACCORD
- Originator
- Accord Healthcare Pty.
- Mechanism
- DNA inhibitor
- Target
- DNA
- Structured fields
- 8
Sponsor / originator context: Accord Healthcare Pty.. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: DNA inhibitor. Target: DNA. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 224 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 1407-GUCG | Phase 3 | Ningbo Cancer Hospital | 2024-513509-30-00 |
| 1438-0011 | Phase 3 | Boehringer Ingelheim | 2025-523869-22-00 |
| 1438-0012 | Phase 3 | Boehringer Ingelheim | 2025-520565-51-00 |
| 1479-0008 | Phase 3 | Boehringer Ingelheim | 2023-504308-27-00 |
| 2019/2894 | Phase 3 | George Institute for | 2024-514917-36-00 |
| 20200041 | Phase 3 | Amgen | 2023-505989-29-00 |
| 20240178 | Phase 3 | Amgen | 2024-520050-38-00 |
| 22615 | Phase 3 | Bayer | 2024-511319-91-00 |
| 61186372HNC3001 | Phase 3 | Janssen-Cilag International N.V | 2025-521917-24-00 |
| 61186372NSC3001 | Phase 3 | Janssen-Cilag International N.V | 2023-506033-29-00 |
| 61186372NSC3002 | Phase 3 | Janssen-Cilag International N.V | 2023-506518-33-00 |
| APHP241011 | Phase 3 | PARItec | 2025-521891-78-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026082899 | ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE | WO |
| 2026068864 | DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE | WO |
| 2026062193 | COMPOSITIONS ET PROCÉDÉS | WO |
| 2026058153 | UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES | WO |
| 2026057625 | PEPTIDOGLYCANE HYDROLASES AYANT UN DOMAINE CHAP AVEC SITE ACTIF MODIFIÉ | WO |
| 2026057626 | PEPTIDOGLYCANE HYDROLASES AYANT DE MULTIPLES DOMAINES ENZYMATIQUEMENT ACTIFS | WO |
| 2026047601 | RÉCEPTEURS DE LYMPHOCYTES T (TCR) | WO |
| 2026033380 | PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES | WO |
| 2026027695 | COMPOSITIONS ET PROCÉDÉS | WO |
| 2026021698 | PARTICULE D'ACIDE NUCLÉIQUE | WO |
| 2026013643 | PROCÉDÉS ET COMPOSITIONS POUR CONCEVOIR DES CHAÎNES D'ÉPITOPES AVEC DES LIEURS | WO |
| 2026015857 | COMPOSITION DE VACCIN DESTINÉE À DÉCLENCHER UNE RÉPONSE DES LYMPHOCYTES T CD8+ SPÉCIFIQUE DE L'EBV | WO |
Related hubs
FAQ
What is the FDA approval status of carboplatin?
carboplatin currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get carboplatin regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to carboplatin?
This spoke lists 224 published programs associated with carboplatin in our pipeline index.